Physician profile
Xiuli Li
NPI 1720229180
$6,329.95
in general payments reported to CMS, 2019-2025
59 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $632 · 2021: $813 · 2022: $1,017 · 2023: $849 · 2024: $613 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.81 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.81 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $714.42 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ge Healthcare | $398.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $389.70 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $237.21 | 2019-2024 | Ultomiris |
| Acadia Pharmaceuticals INC | $232.97 | 2019-2025 | Daybue |
| Neurocrine Biosciences, INC. | $190.65 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $187.02 | 2019-2025 | Vyepti |
| Ucb, INC. | $185.90 | 2019-2024 | Rystiggo |
| Alnylam Pharmaceuticals INC. | $181.98 | 2019-2024 | Onpattro |
| Kyowa Kirin, INC. | $169.95 | 2019-2024 | Nourianz |
| Genzyme Corporation | $152.06 | 2019-2025 | |
| Mdd US Operations, LLC | $135.55 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $124.63 | 2019-2022 | |
| Sk Life Science, INC. | $115.61 | 2023-2025 |
Show all 58 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$649,224.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiuli Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.